Recent trials have suggested that inhibitors of the renin-angiotensin system (RAS), such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin ‖ receptor blockers (ARBs), may reduce the incidence of new-onset of diabetes in patients with or without hypertension and at a higher risk of developing diabetes (1). This evidence concerns the gene REN and diabetes mellitus.